Cargando…
SAT-LB113 Psychosocial Benefits of Using Basal-IQ® Predictive Low Glucose Suspend Technology in a Real-World Setting: Results From Pediatric Patients With Type 1 Diabetes
Recent literature has highlighted remarkable clinical benefits of the Basal-IQ PredictiveLow Glucose Suspend (PLGS) technology for both pediatric and adult patients with type 1diabetes (PwT1D). Although less frequently acknowledged in the literature, psychosocial benefits and other patient-reported...
Autores principales: | Singh, Harsimran, Manning, Michelle, McElwee-Malloy, Molly, Habif, Steph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208362/ http://dx.doi.org/10.1210/jendso/bvaa046.2088 |
Ejemplares similares
-
Virtual Pump Trainings for the t:slim X2 Insulin Pump With Control-IQ Advanced Hybrid Closed-Loop Technology: Real World Patient Experience
por: Singh, Harsimran, et al.
Publicado: (2021) -
Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
por: Pinsker, Jordan E., et al.
Publicado: (2021) -
SAT-LB026 Basal-Prandial Insulin versus Basal-Sliding-Scale Insulin in the Management of Hyperglycemia in Non-Critically Ill Hospitalized Patients
por: Malkhasyan, Victoria, et al.
Publicado: (2019) -
SAT-LB110 Sulfonylurea-Induced Hypoglycemia: To Use Octreotide or Not
por: Romeu, Jose, et al.
Publicado: (2020) -
SAT-LB027 Does Diabetes Education Influence Glycosylated Hemoglobin?
por: Bhargava, Pooja, et al.
Publicado: (2019)